<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30195804</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>09</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1535-6345</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>03</Day>                    </PubDate>                </JournalIssue>                <Title>Current problems in cancer</Title>                <ISOAbbreviation>Curr Probl Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>Risk and survival of chronic myeloid leukemia after breast cancer: A population-based study.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">S0147-0272(18)30091-6</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.currproblcancer.2018.08.005</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We aimed to investigate the risk and survival of chronic myeloid leukemia (CML) after breast cancer (BC) diagnosis.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">We used the Surveillance, Epidemiology, and End Results 'SEER' database. Females, diagnosed with BC between 1992 and 2014, were selected and followed for the development of CML after a 6-month latency period from BC diagnosis. We used the Multiple Primary Standardized Incidence Ratios session of the SEER*Stat software (version 8.3.4) to calculate the Observed/Expected (O/E) ratios with 95% confidence intervals (CI). To calculate the overall survival, we performed an unadjusted Kaplan-Meier analysis using the SPSS software.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We included 474,866 females with BC, of which 178 were later diagnosed with CML. We found the risk of CML to increase significantly after BC diagnosis (O/E = 1.26, 95% CI: 1.08-1.45) and the risk was specifically higher within the first 5 years of diagnosis (O/E = 1.45, 95% CI: 1.16-1.8). When the risk was stratified by cancer stage, localized BC was associated with a significant increase in CML risk within 5 years of diagnosis (O/E = 1.4, 95% CI: 1.06-1.82), while regional BC was associated with a significant increase in CML risk after more than 5 years of diagnosis (O/E = 1.59, 95% CI: 1.09-2.25). Moreover, radiotherapy, chemotherapy, and presence of hormonal receptors were associated with a significant increase in CML risk in BC patients. The median overall survival of CML after BC was 28 months.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Breast cancer patients have an increased risk of developing CML and further investigation is required to establish the causes of this finding.</AbstractText>                <CopyrightInformation>Copyright © 2018. Published by Elsevier Inc.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Al-Husseini</LastName>                    <ForeName>Muneer J</ForeName>                    <Initials>MJ</Initials>                    <AffiliationInfo>                        <Affiliation>Faculty of Medicine, Ain Shams University, Cairo, Egypt.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mohamed</LastName>                    <ForeName>Hadeer H</ForeName>                    <Initials>HH</Initials>                    <AffiliationInfo>                        <Affiliation>Faculty of Medicine, Ain Shams University, Cairo, Egypt.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Saad</LastName>                    <ForeName>Anas M</ForeName>                    <Initials>AM</Initials>                    <AffiliationInfo>                        <Affiliation>Faculty of Medicine, Ain Shams University, Cairo, Egypt.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gad</LastName>                    <ForeName>Mohamed M</ForeName>                    <Initials>MM</Initials>                    <AffiliationInfo>                        <Affiliation>Faculty of Medicine, Ain Shams University, Cairo, Egypt; Cleveland Clinic Foundation, Cleveland, Ohio.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Atia</LastName>                    <ForeName>Mona</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Qaddoora</LastName>                    <ForeName>Umniyah</ForeName>                    <Initials>U</Initials>                    <AffiliationInfo>                        <Affiliation>Faculty of Medicine, Ain Shams University, Cairo, Egypt.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Abushouk</LastName>                    <ForeName>Abdelrahman Ibrahim</ForeName>                    <Initials>AI</Initials>                    <AffiliationInfo>                        <Affiliation>Faculty of Medicine, Ain Shams University, Cairo, Egypt. Electronic address: Abdelrahman.abushouk@med.asu.edu.eg.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Elshinawi</LastName>                    <ForeName>Mohamed E</ForeName>                    <Initials>ME</Initials>                    <AffiliationInfo>                        <Affiliation>General Surgery Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>03</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Curr Probl Cancer</MedlineTA>            <NlmUniqueID>7702986</NlmUniqueID>            <ISSNLinking>0147-0272</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Chemotherapy</Keyword>            <Keyword MajorTopicYN="N">Chronic myeloid leukemia</Keyword>            <Keyword MajorTopicYN="N">Radiotherapy</Keyword>            <Keyword MajorTopicYN="N">SEER</Keyword>            <Keyword MajorTopicYN="N">Survival</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>04</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>17</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30195804</ArticleId>            <ArticleId IdType="pii">S0147-0272(18)30091-6</ArticleId>            <ArticleId IdType="doi">10.1016/j.currproblcancer.2018.08.005</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>